<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204679">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000293</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09259-10</org_study_id>
    <secondary_id>P50-09259-10</secondary_id>
    <nct_id>NCT00000293</nct_id>
  </id_info>
  <brief_title>Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10</brief_title>
  <official_title>Effect of Nefazodone on Relapse in Females With Cocaine Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of nefazodone on relapse to cocaine use
      in depressed and non-depressed females with cocaine abuse/dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effect of nefazodone on relapse to cocaine in
      women and if a greater effect will be seen in the dependent condition. A relapse and coping
      skills questionnaire will be utilized to determine the various factors important to the
      relapse process.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date>December 2001</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Retention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary drug use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression (secondary)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefazodone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female, ages 18-55, cocaine abuse/dependence, use of cocaine 7 days of the last 30 days or
        of the 30 days prior to current abstinence, less than 90 days current abstinence, at least
        an 8th grade education.

        Exclusion Criteria:

        Unstable medical conditions; current use of Hismanal, Seldane, or Propulsid; dx of MR,
        OBS, bipolar, schizophrenia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1999</verification_date>
  <lastchanged_date>August 16, 2005</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nefazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
